Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q3 2025 · 10-Q
Revenue$635.22K$635.22K— vs Q3 2024 Net Income-$1.92M-$1.92MN/M vs Q3 2024 EPS Diluted-$0.11-$0.11N/M vs Q3 2024 Operating Income-$1,945,587N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-306.3%
Net margin-301.9%
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end